Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie (NYSE:ABBV) shares traded in the red on Thursday, making it the seventh consecutive day of losses. The stock closed ...

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

David Risinger’s rating is based on several key considerations surrounding AbbVie’s recent clinical trial outcomes. The company’s announcement on November 11, 2024, revealed that emraclidine’s Phase 2 ...

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...